ClinicalTrials.gg
CompletedNCT06066515SYNCHRONIZE™-1Updated Mar 12, 2026

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight

A Phase 3 interventional study of survodutide and Placebo in Obesity, sponsored by Boehringer Ingelheim. Completed at 118 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-12.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
726
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies testing survodutide in Obesity — 4 open to participants now, 7 under way, 3 of them phase 3. survodutide · Obesity.

Enrollment
3rd of 22
726 · median 121
Started
2023
with 3 others
Phase 3
9 of 22
3 open now
Registered
6th of 22
by date
Lead sponsor
22 of 22
Boehringer Ingelheim

Among the 22 studies testing survodutide in Obesity, this one is the 3rd largest by enrollment, is one of 4 that started in 2023, is one of 9 in phase 3, and was the 6th registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.

Browse Obesity studies →

Open to participants now

4 of the 22 studies testing survodutide in Obesity are open now, in 5 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About survodutide

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies testing survodutide in Obesity, or all of them as a file.
02

Study summary

This study is open to adults who are at least 18 years old and have

  • a body mass index (BMI) of 30 kg/m² or more, or
  • a BMI of 27 kg/m² or more and at least one health problem related to their weight.

People with type 2 diabetes cannot take part in this study. Only people who have previously not managed to lose weight by changing their diet can participate.

The purpose of this study is to find out whether a medicine called survodutide (BI 456906) helps people living with overweight or obesity to lose weight. Participants are divided into 3 groups by chance, like drawing names from a hat. 2 groups get different doses of survodutide and 1 group gets placebo. Placebo looks like survodutide but does not contain any medicine. Every participant has a 2 in 3 chance of getting survodutide. Participants inject survodutide or placebo under their skin once a week for about one and a half years. In addition to the study medicine, all participants receive counselling to make changes to their diet and to exercise regularly.

Participants are in the study for about 1 year and 7 months. During this time, it is planned that participants visit the study site up to 14 times and receive 6 phone calls by the site staff.

The doctors check participants' health and take note of any unwanted effects. The participants' body weight is regularly measured. The results are compared between the groups to see whether the treatment works.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female, age ≥18 years at the time of signing , and at least the legal age of consent in countries where it is >18 years
  2. (BMI) ≥30 kg/m\^2 at screening, OR BMI ≥27 kg/m\^2 with the presence of at least one of the obesity-related complications (treated or untreated) e.g,:

    • Hypertension (defined as repeated, i.e. at least 3 measurements in resting condition, systolic blood pressure (SBP) values of ≥140 millimetre of mercury (mmHg) and/or diastolic blood pressure (DBP) values of ≥90 mmHg in the absence of anti-hypertensive treatment, or intake of at least 1 anti-hypertensive drug to maintain a normotensive blood pressure)
    • Dyslipidaemia (defined as at least 1 lipid-lowering treatment required to maintain normal blood lipid levels, or low-density lipoprotein (LDL) cholesterol ≥160 mg/dL (≥4.1 mmol/L), or triglycerides ≥150 mg/dL (≥1.7 mmol/L), or high-density lipoprotein (HDL) cholesterol \<40 mg/dL (\<1.0 mmol/L) for men or HDL cholesterol 50 mg/dL (\<1.3 mmol/L) for women)
    • Obstructive sleep apnoea
    • Others.
  3. History of at least one self-reported unsuccessful dietary effort to lose body weight.

Further inclusion criteria apply.

Exclusion criteria

Exclusion Criteria:

  1. Body weight change (self-reported) of >5% within 3 months before screening.
  2. Treatment with any medication for the indication obesity within 3 months before screening.
  3. Glycosylated (HbA1c) ≥6.5% (≥48 mmol/mol) as measured by the central laboratory at screening.
  4. History of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) or treatment with glucose lowering agent started within 3 months before the screening up to and including the randomisation visit.
  5. Heart failure (HF) with (NYHA) functional class IV.
  6. Known gastric emptying abnormality (e.g. severe diabetic gastroparesis or gastric outlet obstruction).
  7. History of either chronic or acute pancreatitis or elevation of serum lipase or serum pancreatic amylase >2x (ULN) as measured by the central laboratory at screening.
  8. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Further exclusion criteria apply.

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
726 participants (actual)

Study arms

  • Experimental
    Survodutide 3.6 mg

    Combination Product: survodutide

  • Experimental
    Survodutide 6.0 mg

    Combination Product: survodutide

  • Placebo comparator
    Placebo

    Combination Product: Placebo

Interventions

  • Combination productsurvodutide

    once weekly subcutaneous injection

    Also known as: BI 456906

  • Combination productPlacebo

    once weekly subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percentage change in body weight from baseline to Week 76

    Time frame: Baseline and at Week 76

  2. Achievement of body weight reduction ≥5% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

Secondary outcomes

  1. Achievement of body weight reduction ≥10% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

  2. Achievement of body weight reduction ≥15% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

  3. Achievement of body weight reduction ≥20% (yes/no) from baseline to Week 76

    Time frame: Baseline and at Week 76

  4. Absolute change from baseline to Week 76 in body weight (kg)

    Time frame: Baseline and Week 76

  5. Absolute change from baseline to Week 76 in waist circumference (cm)

    Time frame: Baseline and at Week 76

  6. Absolute change from baseline to Week 76 in systolic blood pressure (SBP) (mmHg)

    Time frame: Baseline and at Week 76

  7. Absolute change from baseline to Week 76 in "Capacity to Resist" domain score of the Eating Behaviour patient reported outcome (PRO)

    "Capacity to Resist" domain score of the Eating Behaviour PRO is ranging between 0 and 24 and a higher score indicates a lower capacity to resist.

    Time frame: Baseline and at Week 76

  8. Absolute change from baseline to Week 76 in Eating Behaviour PRO total score

    Eating Behaviour PRO total score is ranging between 0 and 48 and a higher score indicates a worse eating behaviour (greater desire to eat and/or lower capacity to resist).

    Time frame: Baseline and at Week 76

  9. Absolute change from baseline to Week 76 in body mass index (BMI) (kg/m2)

    Time frame: Baseline and at Week 76

  10. Absolute change from baseline to Week 76 in diastolic blood pressure (DBP) (mmHg)

    Time frame: Baseline and at Week 76

  11. Absolute change from baseline to Week 76 in glycosylated haemoglobin A1c (HbA1c) (%)

    Time frame: Baseline and at Week 76

  12. Absolute change from baseline to Week 76 in HbA1c (mmol/mol)

    Time frame: Baseline and at Week 76

  13. Absolute change from baseline to Week 76 in fasting plasma glucose (FPG) (mg/dL)

    Time frame: Baseline and at Week 76

  14. Absolute change from baseline to Week 76 in fasting plasma insulin (FPI) (mIU/L)

    Time frame: Baseline and at Week 76

  15. Absolute change from baseline to Week 76 in total cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  16. Absolute change from baseline to Week 76 in high density lipoprotein (HDL) cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  17. Absolute change from baseline to Week 76 in low density lipoprotein (LDL) cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  18. Absolute change from baseline to Week 76 in very-low-density lipoprotein (VLDL) cholesterol (mg/dL)

    Time frame: Baseline and at Week 76

  19. Absolute change from baseline to Week 76 in triglycerides (mg/dL)

    Time frame: Baseline and at Week 76

  20. Absolute change from baseline to Week 76 in free fatty acids (mg/dL)

    Time frame: Baseline and at Week 76

  21. Absolute change from baseline to Week 76 in alanine aminotransferase (ALT) (U/L)

    Time frame: Baseline and at Week 76

  22. Absolute change from baseline to Week 76 in aspartate aminotransferase (AST) (U/L)

    Time frame: Baseline and at Week 76

  23. Absolute change from baseline to Week 76 in total fat volume (L)

    Time frame: Baseline and at Week 76

  24. Absolute change from baseline to Week 76 in lean body volume (L)

    Time frame: Baseline and at Week 76

  25. Absolute change from baseline to Week 76 in visceral fat volume (L)

    Time frame: Baseline and at Week 76

  26. Absolute change from baseline to Week 76 in subcutaneous fat volume (L)

    Time frame: Baseline and at Week 76.

  27. Relative change from baseline to Week 76 in total fat volume (%)

    Time frame: Baseline and at Week 76

  28. Relative change from baseline to Week 76 in lean body volume (%)

    Time frame: Baseline and at Week 76

  29. Relative change from baseline to Week 76 in visceral fat volume (%)

    Time frame: Baseline and at Week 76

  30. Relative change from baseline to Week 76 in subcutaneous fat volume (%)

    Time frame: Baseline and at Week 76.

  31. Relative change from baseline to Week 76 in liver fat content (%)

    Time frame: Baseline and at Week 76

07

Study locations

118 sites
  • EmVenio Research-Phoenix-69743
    Phoenix, Arizona 85032, United States
  • Encompass Clinical Research, Spring Valley
    Spring Valley, California 91978, United States
  • Diablo Clinical Research
    Walnut Creek, California 94598, United States
  • Yale University School of Medicine
    New Haven, Connecticut 06519, United States
  • Alliance for Multispecialty Research, LLC - Doral
    Doral, Florida 33172, United States
  • University of Florida
    Gainesville, Florida 32610, United States
  • East Coast Institute for Research, LLC - Jacksonville
    Jacksonville, Florida 32216, United States
  • New Horizon Research Center-Miami-69732
    Miami, Florida 33165, United States
  • West Orange Endocrinology
    Ocoee, Florida 34761, United States
  • East-West Medical Research
    Honolulu, Hawaii 96814, United States
  • Solaris Clinical Research
    Meridian, Idaho 83646, United States
  • Evanston Premier Healthcare Research LLC
    Skokie, Illinois 60077, United States
  • Velocity Clinical Research-Valparaiso-68883
    Valparaiso, Indiana 46383, United States
  • Velocity Clinical Research-Sioux City-69728
    Sioux City, Iowa 51106, United States
  • AMR Lexington
    Lexington, Kentucky 40509, United States
  • L-MARC Research Center
    Louisville, Kentucky 40213, United States
  • StudyMetrix Research, LLC
    City of Saint Peters, Missouri 63303, United States
  • Premier Research, Inc.
    Trenton, New Jersey 08611, United States
  • Velocity Clinical Research - Binghamton
    Binghamton, New York 13905, United States
  • Southgate Medical Group/ Southgate Medical Park
    West Seneca, New York 14224, United States
  • Physicians East, PA
    Greenville, North Carolina 27834, United States
  • Lucas Research, Inc.
    Morehead City, North Carolina 28557, United States
  • Accellacare-Wilmington-67123
    Wilmington, North Carolina 28401, United States
  • Valley Weight Loss Clinic
    Fargo, North Dakota 58104, United States
  • EmVenio Research-Oklahoma City-70053
    Oklahoma City, Oklahoma 73139, United States
  • Trial Management Associates
    Myrtle Beach, South Carolina 29572, United States
  • Texas Diabetes and Endocrinology
    Austin, Texas 78731, United States
  • Juno Research, LLC
    Houston, Texas 77040, United States
  • Diabetes & Glandular Disease Clinic, P.A.
    San Antonio, Texas 78229, United States
  • Consano Clinical Research
    Shavano Park, Texas 78231, United States
  • Manassas Clinical Research Center
    Manassas, Virginia 20110, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Hunter Diabetes Centre
    Merewether, New South Wales 2291, Australia
  • CORE Research Group
    Milton, Queensland 4064, Australia
  • Griffith Health
    Southport, Queensland 4125, Australia
  • Monash University
    Box Hill, Victoria 3128, Australia
  • Austin Health
    Heidelberg, Victoria 3084, Australia
  • Baker Heart and Diabetes Institute
    Melbourne, Victoria 3004, Australia
  • Keogh Institute for Medical Research
    Nedlands, Western Australia 6009, Australia
  • ASZ - Campus Aalst
    Aalst, 9300, Belgium
  • Edegem - UNIV UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • Roeselare - HOSP AZ Delta
    Roeselare, 8800, Belgium
  • Dr. James Lai
    Vancouver, British Columbia V5Z 4E1, Canada
  • Aggarwal and Associates Ltd.
    Brampton, Ontario L6T 0G1, Canada
  • The Wharton Medical Clinic Clinical Trials Inc.
    Hamilton, Ontario L8L 5G8, Canada
  • Milestone Research Inc.
    London, Ontario N5W 6A2, Canada
  • James Cha, MD
    Oshawa, Ontario L1J 2K1, Canada
  • Stouffville Medical Research Institute Inc.
    Stouffville, Ontario L4A 1H2, Canada
  • Albion Finch Medical Centre
    Toronto, Ontario M9V 4B4, Canada
  • Sameh Fikry Medicine Professional Corporation
    Waterloo, Ontario N2J 1C4, Canada
  • ViaCar Recherches Cliniques Inc. (Greenfield Park)
    Greenfield Park, Quebec J4V 2G8, Canada
  • Power Clinical Research
    Montreal, Quebec H3M 1L3, Canada
  • Peking University People's Hospital
    Beijing, 100044, China
  • Beijing Pinggu Hospital
    Beijing, 101200, China
  • The First Hospital of Jilin University
    Changchun, 130021, China
  • Changzhou Second People's Hospital
    Changzhou, 213004, China
  • Guangdong Provincial People's Hospital
    Guangzhou, 510080, China
  • Forth Clinical Hospital of Harbin Medical University
    Harbin, 150599, China
  • Huzhou Central Hospital
    Huzhou, 313000, China
  • Center Hospital of Jinan
    Jinan, 250013, China
  • The First Affiliated Hospital of Henan University of Science and Technology
    Luoyang, 471000, China
  • The Second Affiliated Hospital of Nanjing Medical University
    Nanjing, 210011, China
  • Pingxiang People's Hospital
    Pingxiang, 337000, China
  • Shanghai Municipal Hospital of Traditional Chinese Medicine
    Shanghai, 200071, China
  • Shanghai Fifth People's Hospital affiliated to Fudan University
    Shanghai, 200240, China
  • Siping Central People's Hospital
    Siping, 136000, China
  • Suzhou Municipal Hospital
    Suzhou, 215002, China
  • Tianjin Medical University General Hospital
    Tianjin, 30052, China
  • The First Affiliated Hospital of Xi'an Medical University
    Xi'an, 710077, China
  • The Second Affiliated Hospital of Zhengzhou University
    Zhengzhou, 100029, China
  • Affiliated Hospital of Jiangsu University
    Zhenjiang, 212013, China
  • HUS, Lihavuustutkimusyksikkö Biomedicum Helsinki
    Helsinki, 00290, Finland
  • StudyCor Oy
    Jyväskylä, 40620, Finland
  • Itä-Suomen yliopisto/Health Step Finland Oy
    Kuopio, 70600, Finland
  • CRST - Clinical Research Services Turku
    Turku, 20520, Finland
  • InnoDiab Forschung GmbH
    Essen, 45136, Germany
  • MVZ im Altstadt-Caree Fulda GmbH
    Fulda, 36037, Germany
  • Diabetes Zentrum Hamburg West
    Hamburg, 22607, Germany
  • Institut für Diabetesforschung Münster GmbH
    Münster, 48145, Germany
  • Fukuhama Chuo Clinic
    Fukuoka, Fukuoka, 810-0066, Japan
  • Kobe University Hospital
    Hyogo, Kobe, 650-0017, Japan
  • Noritake Clinic
    Ibaraki, Ushiku, 300-1207, Japan
  • Soka Sugiura Naika Clinic
    Saitama, Soka, 340-0034, Japan
  • Hachioji Diabetes Clinic
    Tokyo, Hachioji, 192-0083, Japan
  • PT & R
    Born, 6121 XK, Netherlands
  • Universitair Medisch Centrum Groningen
    Groningen, 9713 EZ, Netherlands
  • Franciscus Gasthuis
    Rotterdam, 3045 PM, Netherlands
  • P3 Research Dunedin
    Dunedin, 9016, New Zealand
  • Southern Clinical Trials Tasman
    Nelson, 7011, New Zealand
  • P3 Research-Newtown Wellington NZ-33770
    Newtown Wellington NZ, 6021, New Zealand
  • Optimal Clinical Trials North
    Rosedale, Auckland, 0632, New Zealand
  • P3 Research-Tauranga-34833
    Tauranga, 3110, New Zealand
  • PI HOUSE Sp. z o.o., Gdansk
    Gdansk, 80-546, Poland
  • ETG Lublin
    Lublin, 20-412, Poland
  • Velocity Nova Sp z o.o.
    Puławy, 24-100, Poland
  • ETG Siedlce
    Siedlce, 08-110, Poland
  • Clinical Research Center METABOLICA lek. Robert Witek
    Tarnów, 33-100, Poland
  • The Catholic University of Korea, Bucheon St.Mary's Hospital
    Bucheon-si, 14647, South Korea
  • Kyungpook National University Hospital
    Daegu, 41944, South Korea

Showing the first 100 of 118 sites across 14 countries. Choose a country and city above to see the rest.

08

References and documents

Publications

  • le Roux CW, Wharton S, Startseva E, Kloer IM, Hussain SA, Unseld A, Bozkurt B, Ard JD, Bays HE, Bogdanski P, Ekinci EI, Jastreboff AM, Ji L, Ogawa W, Pedersen SD, Pietilainen KH, Sattar N, Seufert J, Stenlof K, van Beek AP, Vangoitsenhoven R, Brueckmann M, Younes R, Kaplan LM; SYNCHRONIZE-1 Investigators. Survodutide Once Weekly for the Treatment of Adults with Obesity. N Engl J Med. 2026 Jun 7. doi: 10.1056/NEJMoa2600751. Online ahead of print. PubMed 42253238 ↗
  • le Roux CW, Wharton S, Bozkurt B, Platz E, Bleckert G, Ajaz Hussain S, Brueckmann M, Startseva E, Kloer IM, Kaplan LM. Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE-1). Diabetes Obes Metab. 2026 Jan;28(1):337-346. doi: 10.1111/dom.70196. Epub 2025 Nov 4. PubMed 41187967 ↗

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section "Time Frame" are fulfilled, researchers can use the following link https://www.clinicalstudies.boehringer-ingelheim.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: After structured results have been posted, all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.

Access criteria: For study documents - upon signing of a 'Document Sharing Agreement'.For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.clinicalstudies.boehringer-ingelheim.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2023 to primary completion in Dec 2025, 24 months.

Of 199 industry-sponsored phase 3 interventional studies under Obesity, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 27. This study's 24 months is above that.

Counting every sponsor, half of 262 studies reached it within 24 months; a quarter within 18 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 27, 2023
First posted
Oct 4, 2023
StartActual
Nov 25, 2023
Primary completionActual
Dec 2, 2025
CompletionActual
Feb 20, 2026
Last update
Mar 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06066515
Responsible party
Sponsor
First posted
Oct 4, 2023
Start date
Nov 25, 2023
Primary completion
Dec 2, 2025
Completion
Feb 20, 2026
Last update
Mar 12, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Survodutide

Start the discussion